Market Place
Sourcing Support
Bio-Path Holdings Reports Third Quarter 2024 Financial Results
15 Nov 2024 //
GLOBENEWSWIRE
Bio-Path Holdings to Announce Q3 2024 Financial Results on Nov 15
08 Nov 2024 //
GLOBENEWSWIRE
Bio-Path Closes $4M Private Placement At-Market Under Nasdaq
10 Oct 2024 //
GLOBENEWSWIRE
Bio-Path Initiates Development Of Obesity Treatment Program
08 Oct 2024 //
GLOBENEWSWIRE
Bio-Path Holdings Announces $4.0 Million Private Placement
08 Oct 2024 //
GLOBENEWSWIRE
Bio-Path Holdings Announces Publication in Biomedicines
16 Sep 2024 //
GLOBENEWSWIRE
Bio-Path Holdings to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
Bio-Path Reports Solid Tumor Response To BP1001-A Treatment
21 Aug 2024 //
GLOBENEWSWIRE
Bio-Path Holdings Reports Second Quarter 2024 Financial Results
15 Aug 2024 //
GLOBENEWSWIRE
Bio-Path Holdings To Announce Q2 2024 Results On August 15, 2024
08 Aug 2024 //
GLOBENEWSWIRE
Bio-Path Holdings Provides Clinical Update and Expansion Plans
08 Jul 2024 //
GLOBENEWSWIRE
Bio-Path Presents Prexigebersen AML Combo Data At EHA 2024
14 Jun 2024 //
GLOBENEWSWIRE
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement
05 Jun 2024 //
GLOBENEWSWIRE
Bio-Path: $4M Private Placement Priced At Nasdaq Market
04 Jun 2024 //
GLOBENEWSWIRE
Bio-Path`s Prexigebersen AML Combo Data At ASCO 2024
03 Jun 2024 //
GLOBENEWSWIRE
Bio-Path Eha 2024 Data: To Be Presented At European Congress
24 May 2024 //
GLOBENEWSWIRE
Bio-Path Asco 2024 Data: To Be Presented At Annual Meeting
23 May 2024 //
GLOBENEWSWIRE
Bio-Path Holdings Reports First Quarter 2024 Financial Results
15 May 2024 //
GLOBENEWSWIRE
Bio-Path Q1 2024 Results On May 15
08 May 2024 //
GLOBENEWSWIRE
Bio-Path Closes $1.2M Registered Direct Offering At Market
19 Apr 2024 //
GLOBENEWSWIRE
Bio-Path Completes Higher Dose AML Trial Cohort For BP1002
18 Apr 2024 //
GLOBENEWSWIRE
Bio-Path Announces $1.2M Registered Direct Offering
18 Apr 2024 //
GLOBENEWSWIRE
Bio-Path Expands Global Patent Portfolio
15 Apr 2024 //
GLOBENEWSWIRE
Bio-Path Holdings Provides 2024 Clinical and Operational Update
02 Apr 2024 //
GLOBENEWSWIRE
Bio-Path Holdings Reports Full Year 2023 Financial Results
08 Mar 2024 //
GLOBENEWSWIRE
Bio-Path to Announce Fourth Quarter and Full Year 2023 Financial Results
01 Mar 2024 //
GLOBENEWSWIRE
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
21 Feb 2024 //
GLOBENEWSWIRE
Bio-Path Announces Completion of First Dose in Phase 1 Trial Evaluating BP1002
10 Jan 2024 //
GLOBENEWSWIRE
Bio-Path Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002
14 Dec 2023 //
GLOBENEWSWIRE
Bio-Path Holdings Reports Third Quarter 2023 Financial Results
15 Nov 2023 //
GLOBENEWSWIRE
Bio-Path to Announce Third Quarter 2023 Financial Results on November 15, 2023
08 Nov 2023 //
GLOBENEWSWIRE
Bio-Path to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen
24 Oct 2023 //
GLOBENEWSWIRE
Bio-Path to Present at H.C. Wainwright 25th Annual Global Investment Conference
08 Sep 2023 //
GLOBENEWSWIRE
Bio-Path Holdings Reports Second Quarter 2023 Financial Results
15 Aug 2023 //
GLOBENEWSWIRE
Bio-Path to Announce Second Quarter 2023 Financial Results on August 15, 2023
08 Aug 2023 //
GLOBENEWSWIRE
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
03 Aug 2023 //
GLOBENEWSWIRE
Bio-Path Holdings Announces Results from Phase 2 of Prexigebersen
01 Aug 2023 //
GLOBENEWSWIRE
Bio-Path Announces Completion of First Dose Cohort in Ph 1/1b Trial of BP1001-A
17 Jul 2023 //
GLOBENEWSWIRE
Bio-Path Holdings Reports First Quarter 2023 Financial Results
12 May 2023 //
GLOBENEWSWIRE
Bio-Path Holdings to Announce First Quarter 2023 Financial Results on
05 May 2023 //
GLOBENEWSWIRE
Bio-Path Holdings Reports Full Year 2022 Financial Results
31 Mar 2023 //
GLOBENEWSWIRE
Bio-Path to Announce Fourth Quarter and Full Year 2022 Financial Results
24 Mar 2023 //
GLOBENEWSWIRE
Bio-Path Holdings Announces First Patient Dosed in Ph 1/1b Trial of BP1001
07 Dec 2022 //
GLOBENEWSWIRE
Bio-Path Holdings, Inc. Announces $2.0 Million Registered Direct Offering
07 Nov 2022 //
GLOBENEWSWIRE
Bio-Path Announces First Patient Dosed in Phase 1/1b Study of BP1002
24 Oct 2022 //
GLOBENEWSWIRE
Bio-Path Holdings to Present at H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
Bio-Path Holdings Reports Second Quarter 2022 Financial Results
16 Aug 2022 //
GLOBENEWSWIRE
Bio-Path Holdings to Announce Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
Bio-Path Holdings Reports First Quarter 2022 Financial Results
17 May 2022 //
GLOBENEWSWIRE
Bio-Path Holdings to Announce First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Bio-Path Holdings Appoints Aline Sherwood to Board of Directors
06 Apr 2022 //
GLOBENEWSWIRE
Bio-Path Holdings Reports Full Year 2021 Financial Results
11 Mar 2022 //
GLOBENEWSWIRE
Bio-Path Holdings to Present at the 2022 AACR
08 Mar 2022 //
GLOBENEWSWIRE
Bio-Path Holdings to Present Clinical Data at ASH 2021
04 Nov 2021 //
GLOBENEWSWIRE
Bio-Path Holdings Announces Clearance INDA for Ph 1/1bTrial of Prexigebersen-A
27 Oct 2021 //
BIOPATHHOLDINGS
Bio-Path Holdings Announces Clearance of IND Application for BP1002 in r/r AML
24 Aug 2021 //
GLOBENEWSWIRE
Bio-Path Holdings Reports Second Quarter 2021 Financial Results
13 Aug 2021 //
GLOBENEWS WIRE
Bio-Path Holdings to Announce Second Quarter 2021 Financial Results
06 Aug 2021 //
GLOBENEWSWIRE
Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003
22 Jun 2021 //
GLOBENEWSWIRE
Bio-Path Announces Publication in Biomedicines
22 Apr 2021 //
GLOBENEWSWIRE
